Can Alnylam’s AMVUTTRA become a first-line treatment force in ATTR-CM?
ATTR-CM treatment is shifting earlier. Alnylam must now prove AMVUTTRA can win clinician trust beyond trial subgroups.
Pharma & Biotech
Pharma & Biotech
Why Avidity is spinning off Atrium Therapeutics before the Novartis acquisition closes
Avidity Biosciences sets spin-off record date for Atrium ahead of Novartis deal. Find out what this carve-out reveals about RNA platform risk and M&A strategy.